1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603.
2. Frangogiannis NG. Pathophysiology of Myocardial Infarction. Compr Physiol. 2015;5(4):1841-75.
3. Dugani SB, Fabbri M, Chamberlain AM, Bielinski SJ, Weston SA, Manemann SM, et al. Premature Myocardial Infarction: A Community Study. Mayo Clin Proc Innov Qual Outcomes. 2021;5(2):413-22.
4. Gabriel-Costa D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology. 2018;25(4):277-84.
5. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. European Heart Journal. 2017;38(11):774-84.
6. Chaqour B, Karrasch C. Eyeing the Extracellular Matrix in Vascular Development and Microvascular Diseases and Bridging the Divide between Vascular Mechanics and Function. Int J Mol Sci. 2020;21(10).
7. Nielsen SH, Mouton AJ, DeLeon-Pennell KY, Genovese F, Karsdal M, Lindsey ML. Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes. Matrix Biology. 2019;75-76:43-57.
8. Rahman MT, Muppala S, Wu J, Krukovets I, Solovjev D, Verbovetskiy D, et al. Effects of thrombospondin-4 on pro-inflammatory phenotype differentiation and apoptosis in macrophages. Cell Death & Disease. 2020;11(1):53.
9. Wight TN, Kang I, Evanko SP, Harten IA, Chang MY, Pearce OMT, et al. Versican—A Critical Extracellular Matrix Regulator of Immunity and Inflammation. Frontiers in Immunology. 2020;11.
10. Kirk JA, Cingolani OH. Thrombospondins in the transition from myocardial infarction to heart failure. J Mol Cell Cardiol. 2016;90:102-10.
11. Stenina-Adognravi O, Plow EF. Thrombospondin-4 in tissue remodeling. Matrix Biology. 2019;75-76:300-13.
12. Zhong S, Khalil RA. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease. Biochemical Pharmacology. 2019;164:188-204.
13. Wu H, Zhang G, Li Z, Ma J, Han X, Xiang T, et al. Thrombospondin-4 expression as a prognostic marker in hepatocellular carcinoma. Gene. 2019;696:219-24.
14. Palao T, Medzikovic L, Rippe C, Wanga S, Al-Mardini C, van Weert A, et al. Thrombospondin-4 mediates cardiovascular remodelling in angiotensin II-induced hypertension. Cardiovascular Pathology. 2018;35:12-9.
15. Andrés Sastre E, Maly K, Zhu M, Witte-Bouma J, Trompet D, Böhm AM, et al. Spatiotemporal distribution of thrombospondin-4 and -5 in cartilage during endochondral bone formation and repair. Bone. 2021;150:115999.
16. Alehagen U, Shamoun L, Wågsäter D. Increased cardiovascular mortality in females with the a/a genotype of the SNPs rs1478604 and rs2228262 of thrombospondin-1. BMC Medical Genetics. 2020;21(1):179.
17. Butnariu LI, Florea L, Badescu MC, Țarcă E, Costache I-I, Gorduza EV. Etiologic Puzzle of Coronary Artery Disease: How Important Is Genetic Component? Life [Internet]. 2022; 12(6).
18. Forbes T, Pauza AG, Adams JC. In the balance: how do thrombospondins contribute to the cellular pathophysiology of cardiovascular disease? American Journal of Physiology-Cell Physiology. 2021;321(5):C826-C45.
19. Abdelmonem NA, Turky NO, Hashad IM, Abdel Rahman MF, El-Etriby A, Gad MZ. Association of Thrombospondin-1 (N700S) and Thrombospondin-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians. Curr Pharm Biotechnol. 2017;18(13):1078-87.
20. Muppala S, Rahman MT, Krukovets I, Verbovetskiy D, Pluskota E, Fleischman A, et al. The P387 Thrombospondin-4 Variant Promotes Accumulation of Macrophages in Atherosclerotic Lesions. bioRxiv. 2019:666602.
21. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Thrombospondins: A Role in Cardiovascular Disease. Int J Mol Sci. 2017;18(7).
22. Zhou X, Huang J, Chen J, Zhao J, Yang W, Wang X, et al. Thrombospondin-4 A387P polymorphism is not associated with coronary artery disease and myocardial infarction in the Chinese Han population. Clin Sci (Lond). 2004;106(5):495-500.
23. Ferry AV, Anand A, Strachan FE, Mooney L, Stewart SD, Marshall L, et al. Presenting Symptoms in Men and Women Diagnosed With Myocardial Infarction Using Sex‐Specific Criteria. Journal of the American Heart Association. 2019;8(17):e012307.
24. Zierfuss B, Höbaus C, Herz CT, Pesau G, Koppensteiner R, Schernthaner GH. Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes. Heart Vessels. 2020;35(1):52-8.
25. Rincón LM, Sanmartín M, Alonso GL, Rodríguez JA, Muriel A, Casas E, et al. A genetic risk score predicts recurrent events after myocardial infarction in young adults. Revista Española de Cardiología (English Edition). 2020;73(8):623-31.
26. Han Y, Teng X, Liu Z. The role of thrombospondin-4 in cardiovascular diseases. Int J Clin Exp Med. 2020;13(2):358-70.
27. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001;104(22):2641-4.
28. Wessel J, Topol EJ, Ji M, Meyer J, McCarthy JJ. Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. Am Heart J. 2004;147(5):905-9.
29. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347(24):1916-23.
30. Zhang XJ, Wei CY, Li WB, Zhang LL, Zhou Y, Wang ZH, et al. Association between single nucleotide polymorphisms in thrombospondins genes and coronary artery disease: A meta-analysis. Thromb Res. 2015;136(1):45-51.